| Drug Name |
Liraglutide |
| Drug ID |
BADD_D01298 |
| Description |
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist[Label,A6932]. Liraglutide is 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34[A6932]. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor[A6932]. Liraglutide was granted FDA approval on Januray 25, 2010[L6070]. |
| Indications and Usage |
Liraglutide is indicated in combination with diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus[Label,L6718]. It is also indicated to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus as well as cardiovascular disease[Label]. |
| Marketing Status |
approved |
| ATC Code |
A10BJ02 |
| DrugBank ID |
DB06655
|
| KEGG ID |
D06404
|
| MeSH ID |
D000069450
|
| PubChem ID |
16134956
|
| TTD Drug ID |
D03GOI
|
| NDC Product Code |
52221-122; 71052-126; 66558-0193; 50090-4503; 76177-118; 0420-9006; 41524-0011; 50090-2853; 65129-1375; 14403-0009; 69766-034; 0169-4060; 70155-003; 71796-022; 0169-2800; 32861-0003 |
| UNII |
839I73S42A
|
| Synonyms |
Liraglutide | Victoza | Saxenda | NN 2211 | 2211, NN | NN2211 | NN-2211 |
